Mosquera Orgueira, Adrian http://orcid.org/0000-0003-4838-6750
González Pérez, Marta Sonia
Diaz Arias, Jose
Rosiñol, Laura http://orcid.org/0000-0002-2534-9239
Oriol, Albert http://orcid.org/0000-0001-6804-2221
Teruel, Ana Isabel
Martinez Lopez, Joaquin
Palomera, Luis
Granell, Miguel http://orcid.org/0000-0002-0366-3673
Blanchard, Maria Jesus
de la Rubia, Javier http://orcid.org/0000-0002-8354-768X
López de la Guia, Ana
Rios, Rafael http://orcid.org/0000-0001-8193-1402
Sureda, Anna
Hernandez, Miguel Teodoro http://orcid.org/0000-0002-6576-7881
Bengoechea, Enrique
Calasanz, María José
Gutierrez, Norma
Martin, Maria Luis
Blade, Joan http://orcid.org/0000-0002-4563-3405
Lahuerta, Juan-Jose http://orcid.org/0000-0002-3393-9570
San Miguel, Jesús http://orcid.org/0000-0002-9183-4857
Mateos, Maria Victoria http://orcid.org/0000-0003-2390-1218
Mosquera Orgueira, Adrian
González Pérez, Marta Sonia
Diaz Arias, Jose
Rosiñol, Laura
Oriol, Albert
Teruel, Ana Isabel
Martinez Lopez, Joaquin
Palomera, Luis
Granell, Miguel
Blanchard, Maria Jesus
de la Rubia, Javier
López de la Guia, Ana
Rios, Rafael
Sureda, Anna
Hernandez, Miguel Teodoro
Bengoechea, Enrique
Calasanz, María José
Gutierrez, Norma
Martin, Maria Luis
Blade, Joan
Lahuerta, Juan-Jose
San Miguel, Jesús
Mateos, Maria Victoria
,
Article History
Received: 22 December 2021
Revised: 5 March 2022
Accepted: 11 March 2022
First Online: 25 April 2022
Competing interests
: The authors declare that no support was provided in the forms of grants and/or equipment and grants for the development of this study. M.-V.M. has received honoraria for lectures and participation in advisory boards from Janssen, Celgene-BMS, Amgen, Takeda, Abbvie, GSK, Adaptive, Roche, Seattle Genetics, Pfizer, and Regeneron. A.M.O reports honoraria for lectures and participation in advisory boards from Janssen, Takeda, Abbvie, Amgen, Novartis, Gilead and AstraZeneca; research grants from Roche, Pfizer and Celgene-BMS and funds for conference organization from Jassen, Takeda, Abbvie, Amgen, Novartis, Gilead, Roche, Bristol-Myers-Squibb, Glaxo-Smith-Klyne, Incyte and Pfizer. M.S.G.P. has received honoraria for lectures and participation in advisory boards from Janssen, Amgen, Celgene-BMS, Takeda, Sanofi and GSK. J.A.D.A.: has received honoraria for lectures from Abbvie and Janssen. L.R. reports Honoraria from Janssen, BMS-Celgene, Amgen, TAkeda, Sanofi, GSK and Karyopharm. A.O. reports advisory board fees from Bristol Myers Squibb, Janssen, and Amgen. A.I.T.: no COIs to disclose. L.P.: no COIs to disclose. M.T.H.: no COIs to disclose. E.B.: no COIs to disclose. M.G. has received honoraria from Janssen-Cilag and Celgene. M.J.B. declares honoraria from lectures and advisory boards from Janssen, BMS/Celgene, Amgen, Takeda, and GSK. J.d.l.R. has served as a consultant and provided expert testimony within the past 2 years for Amgen, Celgene, Takeda, Janssen, and Sanofi. A.L. has received honoraria for advisory boards from Celgene, Amgen, and Janssen. A.S. reports honoraria from Takeda, BMS, MSD, Sanofi, Roche, Novartis y Janssen; consultancy: Takeda, BMS, Novartis, Jansser, Gilead, Sanofi, GSK; Speaker’s bureau: Takeda; Research Support: Takeda. M.J.C.: no COIs to disclose. R.R. has received honoraria for lectures and participation in advisory boards from Becton-Dickinson, Celgene, Janssen, Sanofi and Binding Site. J.M.L. has received honoraria for lectures and participation in advisory boards from Janssen, Celgene-BMS, Amgen, Takeda, Abbvie, GSK, Adaptive, Roche, Pfizer, and Astellas, Incyte. He has received research grants from BMS, Roche, Astellas and Janssen. J.B. reports honoraria from Janssen, Celgene, Takeda, Amgen and Oncopeptides. J.J.L. reports a consulting or advisory role for Celgene, Takeda, Amgen, Janssen and Sanofi and travel accommodations and expenses from Celgene. J.F.S.M. reports a consultancy or advisory role for AbbVie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm, MSD, Novartis, Roche, Sanofi, SecuraBio and Takeda.